Clinical manifestations of atherosclerotic disease include coronary artery disease (CAD), peripheral artery disease (PAD), and stroke. Although the role of platelets is well established, evidence is now accumulating on the contribution of coagulation proteins to the processes of atherosclerosis and atherothrombosis. Coagulation proteins not only play a role in fibrin formation and platelet activation, but also mediate various biological and pathophysiologic processes through activation of protease-activatedreceptors (PARs). Thus far, secondary prevention in patients with CAD/PAD has been the domain of antiplatelet therapy, however, residual atherothrombotic risks remain substantial. Therefore, combining antiplatelet and anticoagulant therapy has gained more attention. Recently, net clinical benefit of combining aspirin with low-dose rivaroxaban in patients with stable atherosclerotic disease has been demonstrated. In this review, based on the State of the Art lecture "Clotting factors and atherothrombosis" presented at the ISTH Congress 2017, we highlight the role of coagulation proteins in the pathophysiology of atherothrombosis, and specifically focus on therapeutic strategies to decrease atherothrombotic events by optimization of vascular protection.
| INTRODUCTION
In the broad category of arterial thrombosis, one can distinguish thrombosis related to atherosclerosis, called atherothrombosis, and arterial thromboembolism, eg, as a consequence of atrial fibrillation. Clinical manifestations of atherothrombosis occur in the heart (coronary artery disease [CAD] , myocardial infarction), the peripheral arterial vasculature (peripheral artery disease [PAD] ) and in the brain (ischemic stroke). Traditionally,
| PATHOPHYSIOLOGY

| Mechanisms of thrombosis in atherosclerosis
The pathogenesis of atherothrombotic events starts with disruption of an atherosclerotic plaque, thereby exposing thrombogenic material to the blood. 5 Thrombus formation is driven by coordinated platelet and thrombin generation pathways. Platelets adhere to exposed subendothelial collagen and von Willebrand factor (vWF), become activated, and then release ADP and thromboxane A2 (TXA2), which activate other platelets. Platelet activation induces conformational changes in glycoprotein (GP) IIb/IIIa, which increases the affinity for its ligands fibrinogen and vWF, and thereby mediates platelet aggregation. Simultaneously with platelet activation and aggregation, the transmembrane receptor TF in the plaque binds to factor VII(a) in blood and coagulation is triggered, resulting in thrombin generation.
Thrombin is a key enzyme in that it not only converts fibrinogen into fibrin, but also is a potent platelet agonist via activation of protease-activated receptor (PARs)-1 and 4. Furthermore, thrombin also drives several feedback loops that include activation of factors V, VIII, and XI to further amplify thrombin generation; eventually, factor XIII is activated to cross-link fibrin to stabilize the clot. The amplification phase of coagulation requires a phospholipid surface providing phosphatidylserine (PS) on which the intrinsic tenase (a complex of factor IXa and factor VIIIa) and prothrombinase (factor Xa and factor Va) complexes assemble. 6 This phospholipid surface is primarily provided by activated platelets at the site of plaque rupture, and thereby, the platelet pathway and thrombin pathway are connected.
Pathological examination of coronary artery thrombi removed by thrombectomy or collected after autopsies of fatal myocardial infarction, has shown that thrombi in coronary arteries often have a white, platelet-rich head, which forms at the site of plaque rupture, while its distal extension is red in color, reflecting its fibrin-and erythrocyte-rich tail, which forms when blood flow is reduced. 5, 9, 10 Platelets dominate this process in the first 3-4 hours, whereas fibrin becomes the dominant component at a later time point. These studies confirm that both platelet and thrombin pathways are involved in thrombus formation on an atherosclerotic background.
| Associations of coagulation factors with atherosclerotic plaque progression
Numerous coagulation proteins have been implicated in proinflammatory conditions, such as atherosclerosis. The presence of TF, considered the primary physiologic trigger of the coagulation cascade, in atherosclerotic lesions was shown by studies of Wilcox et al. 11, 12 TF was found on the membrane of macrophages and vascular smooth muscle cells, where it co-localizes with factor VII. Several clinical studies [13] [14] [15] indicate that levels of TF are significantly higher in lesions obtained from patients with unstable angina or myocardial infarction than in those from patients with stable coronary artery disease. The role of these coagulation proteins in atherosclerotic lesions was more extensively studied by Borissoff et al., who examined the presence and activity of relevant coagulation proteins in early and stable advanced atherosclerotic lesions. 16 TF, thrombin, factor X, and FXII activities were significantly higher in early atherosclerotic lesions than in stable advanced atherosclerotic lesions. Furthermore, endogenous thrombin potential and thrombin-antithrombin (TAT) complex values indicated a procoagulant profile of early atherosclerotic lesions as compared to stable advanced atherosclerotic lesions. Even in subclinical atherosclerotic disease, such as individuals with increased carotid intima media thickness (IMT), a relation between TF and IMT as marker of early atherosclerosis has been documented. 17 The presence of coagulation components in atherosclerotic lesions suggests at least a role of these coagulation proteins in plaque thrombogenicity. Taking it one step further, the question rises whether some of these coagulation proteases like thrombin and factor Xa really drive atherogenesis up to the point of atherothrombosis. The fact that coagulation proteins are more present in early atherosclerotic lesions compared to advanced atherosclerotic lesions, 16 supports an important role for these coagulation proteins in the initial development of atherosclerosis, rather than involvement limited to thrombus formation in unstable plaques solely. If so, one would expect some sort of protective effect of factor deficiencies like hemophilia against atherosclerotic disease. Although mouse models suggest that hypocoagulability in hemophilia protects against atherosclerosis, studies in patients with a factor VIII or IX deficiency clearly show that these patients have the same degree of atherosclerosis burden as the general population. 18, 19 When explaining these apparently conflicting findings between mice and hemophilia patients, the use of factor concentrates in humans should be taken into account, although supplementation will never be complete. The signal of lower cardiovascular mortality in patients with hemophilia, 20 albeit not significant (standardized mortality ratio 0.51, 95% CI 0.24-1.09), might not be explained by a reduction in atherosclerotic burden, but by reduced thrombus formation due to hypocoagulability, possibly in combination with increased plaque stability due to reduced thrombin generation. 19 More recently, factor XI deficiency was shown to slow down atherogenesis in mice, with a prominent reduction of macrophage infiltration in the atherosclerotic lesions, as marker of reduction of inflammatory activity in the vessel wall of these mice. 21 Moreover, another coagulation protein of the contact activation system, factor XII, has recently been shown to play an important role in atherosclerotic lesion formation by functioning as a strong inducer of pro-inflammatory cytokine responses in macrophages. 22 Factor XIIa may under certain conditions not only contribute to arterial thrombus formation, but also contribute to inflammation through the activation of the inflammatory kallikrein-kinin system, as reviewed by Nickel et al. 23 
| PAR activation
Besides their activity in coagulation, the TF-VIIa complex, factor Xa and thrombin each can signal through activation of PARs, and thereby, coagulation and inflammatory pathways are connected, as illustrated in Figure 1 . Via PAR-activation, the serine proteases from the clotting system are engaged in several processes, including leucocyte transmigration, vascular remodeling, angiogenesis, and inflammation, which F I G U R E 1 Pathways involved in arterial thrombus formation. An atherothrombotic event starts with disruption of an atherosclerotic plaque, thereby exposing collagen, vWF, TF, and factor XII to the blood. A dual pathway of platelet activation/aggregation and coagulation activation ultimately leads to formation of an arterial thrombus, composed of platelets and fibrin. The interplay between thrombin and platelets is illustrated via the activation of PARs, and via the procoagulant platelet surface as a site for assembly of the tenase and prothrombinase complexes, required for the propagation phase of coagulation. 29 For example, plasma fibrinogen shows a strong and consistent association (OR 1.78, 95% CI 1.69-1.86) with coronary heart disease, although this may partially reflect its inflammatory marker status, as its concentration is increased under the influence of proinflammatory mediators such as interleukin-6. 30 Also more integral tests, like in vitro thrombin generation tests, have been studied in relation to cardiovascular disease. 31 Risks for (recurrent) cardiovascular events are highly variable among individual patients, and from that perspective, the use of biomarkers could potentially help to identify patients at greatest risk to stratify therapy accordingly. Although there is no evidence linking thrombin production to cardiovascular mortality, the downstream fibrin split product D-dimer is associated with cardiovascular events, including mortality in patients with PAD. Future studies using a combination of these different groups of biomarkers may increase the accuracy of risk prediction, and should explore their role in personalizing antithrombotic strategies in high-risk cardiovascular disease patients.
| THERAPEUTIC STRATEGIES IN ATHEROTHROMBOTIC DISEASE
Based on the associations between the coagulation system and atherothrombosis, and above mentioned experimental studies, evidence is accumulating that the coagulation system plays an important role in atherogenesis, plaque (in)stability and consecutive athero- 
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Extended duration of dual therapy with ticagrelor and aspirin beyond the first year in patients with prior myocardial infarction reduced the composite endpoint of cardiovascular death, stroke, and myocardial infarction, however, this benefit comes with a significant increase in major bleeding and no overall mortality benefit. 40 Despite intensification of antiplatelet therapy in recent years, there remains an approximately 10% risk for recurrent ischemic events at 1 year after coronary events. 34, 35 Even higher seems the risk for cardiovascular events in patients with symptomatic peripheral artery disease (PAD) 41, 42 ; current guidelines 43, 44 recommend monotherapy with aspirin or clopidogrel to reduce the risk of myocardial infarction (MI), stroke, or vascular death, but despite the use of antiplatelet therapy an approximately 20% risk for recurrent ischemic events, rehospitalization or death at 1 year remains. 41 In PAD patients, ticagrelor was not superior to clopidogrel in reducing major adverse cardiovascular events (MACE) and acute limb ischemia. 45 According to analysis of PAD patients in the CHARISMA trial, DAPT vs aspirin alone was not able to reduce this high risk for recurrent events in PAD patients, whereas the risk of minor bleeding was increased. 46 In a subgroup analysis of patients with a history of myocardial infarction and concomitant PAD in the PEGASUS trial, the combination of ticagrelor and aspirin reduced both MACE and major adverse limb events (MALE) compared to aspirin alone. 47 However, in this subgroup of patients with concomitant PAD and CAD treated with ticagrelor and aspirin, the incidence of MACE during 3 years follow-up was still as high as 15.2%. Thus, despite antiplatelet therapy, high morbidity and mortality remains in all patients with atherosclerosis, with the highest rates in those with PAD. Moreover, patients with PAD or CAD often have polyvascular disease, and those patients have an even higher risk of morbidity and mortality than patients with only one affected vascular bed. 41, 42 With blockade of the TXA2 pathway and the P2Y12 receptor, platelets can still be activated by thrombin, via the PAR-1 receptor.
In an attempt to further optimize antiplatelet therapy, the selective PAR-1 antagonist vorapaxar was developed. Vorapaxar blocks thrombin-mediated platelet activation, but does not inhibit other modes of thrombin activity, such as fibrin formation, protein C activation, and PAR-4 activation. 48 The combination of three antiplatelet agents in stable ACS patients in the TRA-2°P-TIMI 50 study, involving aspirin, clopidogrel, and the PAR-1 inhibitor vorapaxar, led to significant reduction in rates of ischemic cardiovascular events, but at the price of increased major bleeding. 49 In a subgroup analysis of PAD patients, the addition of vorapaxar to standard therapy with aspirin and/or clopidogrel did not reduce the risk of CV death, myocardial infarction, or stroke when compared with placebo. 49, 50 However, it did result in significant risk reduction in limb outcomes, such as acute limb ischemia, (non-) urgent peripheral revascularization and hospitalization. However, again, intensification of antiplatelet therapy was accompanied by an increased risk of bleeding, especially intracranial bleeding. 50 Hence, according to current guidelines, the overall clinical benefit of vorapaxar added to standard antiplatelet therapy in PAD patients is uncertain. 43 Nevertheless, the beneficial effect of study. 53 However, despite efficacy in the setting of secondary prevention of cardiovascular disease, the combination of aspirin and warfarin increased bleeding and did not reduce mortality. [54] [55] [56] Moreover, after introduction of DAPT, therapy with VKA in the setting of ACS, or percutaneous coronary intervention (PCI) was practically abandoned due to more effective protection of DAPT, in particular against instent thrombosis. 57, 58 In patients with PAD, the combination of aspirin and warfarin did not reduce major cardiovascular complications and markedly increased bleeding. 59 However, a post hoc analysis that excluded patients with fatal bleeding and hemorrhagic stroke from the co-primary outcome demonstrated risk reductions that were more favorable with combination therapy than with antiplatelet therapy alone, suggesting that the excess bleeding neutralized the potential benefit of combination therapy in PAD patients. 59 Nonetheless, the results with warfarin had provided proof-ofprinciple that inhibition of coagulation may be of additional benefit in atherothrombotic disease, a process previously thought to be predominantly platelet-driven. Therefore, after the introduction of direct oral anticoagulants (DOACs), several phase II and later two phase III trials evaluated their role in prevention of recurrent ischemia in stabilized ACS patients. The APPRAISE-2 trial (APixaban for Prevention of Acute Ischaemic Events) was terminated early after recruitment of almost 7400 patients, because of an increase in major bleeding with apixaban at a dose of 5 mg twice daily, without a reduction in recurrent ischemic events. 60 However, the ATLAS-2 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome) was carried to completion and met its primary objective. 61 In this study, 15,526 patients with a recent acute coronary syndrome were randomized to receive twicedaily doses of either 2. To overcome the increased bleeding risk of triple therapy in ATLAS-2, the GEMINI-ACS-1 trial was set up to explore the safety of a dual pathway antithrombotic therapy approach with low-dose rivaroxaban (2.5 mg B.I.D), in place of aspirin, together with a P2Y12 inhibitor (clopidogrel or ticagrelor) in 3037 post-acute ACS patients. 62 Compared to patients in the standard treatment arm with aspirin and a P2Y12 inhibitor, patients in the rivaroxaban plus P2Y12 inhibitor arm had similar rates of clinically significant bleeding. Although clearly undersized for ischemic events, the composite ischemic endpoint of cardiovascular death, myocardial infarction, stroke or stent thrombosis was similar in both groups.
Very recently, results of the COMPASS-trial (Cardiovascular
OutcoMes for People using Anticoagulation StrategieS) were published. 63 This study tested the hypothesis of anticoagulation as a superior strategy as compared to antiplatelet therapy alone in secondary cardiovascular prevention. 64 Following a planned interim analysis the n/a n/a ↑ CAPRIE [99] Ticagrelor n/a n/a ↓ [61] n/a n/a n/a n/a ↑↑↑ ATLAS ACS 2-TIMI 51 [61] Aspirin 95% CI 0.66-0.86). Although there was an increase in major bleeding (HR 1.70, 95% CI 1.40-2.05), there was no significant difference in intracranial or fatal bleeding between these two groups. Treatment with a combination of very-low dose rivaroxaban and aspirin provided a clear net clinical benefit, both in patients with CAD and PAD. For the latter, a group of patients with either peripheral artery disease or carotid artery disease, not only major adverse cardiovascular events (MACE) were significantly reduced, but there was also a significant reduction in major adverse limb events (MALE) and amputations for patients treated with the combination of rivaroxaban and aspirin. 65 As described above, no other pharmaceutical therapy in PAD patients had shown such a clear reduction in both cardiovascular and limb events thus far ( Table 1 ). The relative risk reduction with combination therapy compared to aspirin alone was demonstrated in all patient groups, including patients with carotid artery disease, PAD, or CAD.
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| PLEIOTROPIC EFFECTS OF ANTICOAGULANTS
What is at the basis of this beneficial effect of adding low-dose rivaroxaban to aspirin? It is likely that the benefit of factor Xa and thrombin inhibition in this setting reflects not only attenuation of coagulation, but also inhibition of thrombin-mediated platelet activation, and sup- However, the curves continue to divert throughout the whole study, suggesting that not only existing atherosclerotic lesions are stabilized, but also pro-inflammatory activities in the development of atherosclerosis are inhibited. Such additional effects of DOACs have been strongly suggested by several preclinical models. In animal studies, dabigatran reduced the size of atherosclerotic lesions and enhanced plaque stability. 67, 68 Comparable animal studies with direct Xa inhibitors showed similar beneficial effects on atherosclerosis. 69, 70 These beneficial effects of DOACs on atherosclerosis and atherothrombosis are thought to be due to inhibition of thrombin's PAR-mediated signaling. 24, 27 These pleiotropic effects have also been suggested in other models, such as in myocardial ischemia-reperfusion models,
where rivaroxaban improved cardiac function through the reduction of inflammation in the left ventricle of mice. 71 Factor Xa is thought to elicit a pro-inflammatory response by directly activating PAR-2 receptors, whereas inhibition of factor Xa, and thereby attenuating thrombo-inflammation, might be part of the beneficial effect of rivaroxaban in this setting. Whether such pleiotropic effects would also appear in the human vasculature is not yet elucidated. Nevertheless, the marked reduction in major adverse limb events and amputations in the PAD subset from the COMPASS trial may hint towards an effect on atherosclerosis rather than "simply" on thrombosis. 65 77 concluded that the use of dabigatran was associated with an increased risk of MI, a post-hoc analysis of revised data from the RELY trial 78 and other meta-analyses did not confirm this finding. 79 The potential underlying mechanisms of the suggested increase in MI associated with dabigatran is not clear. Some speculated that the combination of TF-and contact-activation-generated thrombin at the site of coronary plaque rupture might overwhelm the local concentrations of dabigatran. 80 Ex vivo, plasma samples from warfarin-administered patients generated lower peak thrombin levels than those from dabigatranadministered patients, and the authors speculate that the reduced ability of dabigatran to counter the high concentrations of thrombin that are generated by TF after a ruptured atherosclerotic plaque might explain the difference in MI in patients on dabigatran compared to warfarin. 81 
| PRECAUTIONS
| FUTURE PERSPECTIVES
The results of the COMPASS trial might change the field of antithrombotic treatment in patients with atherosclerotic disease. Future studies will have to focus on further implementation and challenges of combined anticoagulant and antiplatelet agents, for example a headto-head comparison between the addition of a second antiplatelet drug vs a very low dose of a factor-Xa inhibitor to aspirin. Moreover, these future studies should focus on the identification of patient groups that are likely to benefit the most of combining anticoagulant and antiplatelet treatment.
Besides, the search for potential new anticoagulants will continue.
The contribution of the proteins of the contact system (factors VIII, IX, XI, XII, prekallikrein, and high-molecular-weight kininogen) to the process of atherothrombosis have recently gained more attention. 82 Not only fibrin formation and the strength of the fibrin clot is stimulated by several steps of the contact system, it also attenuates the fibrinolytic pathway. 83 Currently, specific inhibitors against factors XIIa and XIa are being studied as potential therapeutic targets for prevention of thrombosis. 23, 84, 85 Factor XII deficient humans have a normal hemostatic capacity, while patients lacking factor XI only have a mild trauma-induced bleeding disorder. Contrary to their role in normal hemostasis, animal models revealed a more important role of FXIIa-driven coagulation in arterial thrombosis, 86 and furthermore, factor XIIa contributes to inflammation through the activation of the inflammatory bradykinin-producing kallikrein-kinin system. 22, 23 Besides attenuation of coagulation, factor XI deprivation has also been shown to slow down atherogenesis in apoE/factor XI double knockout mice. 21 Thus, pharmacological inhibition of factors XI(a) and XII(a) interferes with both thrombosis and inflammation, and targeting the FXIIa-driven contact system may eventually be a safe therapeutic strategy, potentially with additional beneficial anti-inflammatory and anti-atherogenic effects.
Although the link between inflammation and atherosclerosis is known for several decades, 2,3 only very recently clinical data demonstrating a direct benefit of targeting inflammation in patients with atherosclerotic disease have become available. Results of the CANTOS trial showed that in patients with prior myocardial infarction with elevated biomarkers of inflammation (hsCRP), anti-inflammatory therapy with canacinumab (an IL-1β blocker) reduced the incidence of recurrent cardiovascular events. 87 However, due to safety concerns (more fatal infections) and costs, it is currently unclear whether canakinumab or other anti-inflammatory therapies will ultimately be used in highrisk patients with atherosclerotic disease.
| ISTH BERLIN REPORT
Lind and colleagues report that incident VTE was associated with progression of existing carotid atherosclerotic lesions, but not with new plaques in an analysis from the Tromsø study. 88 Importantly, this effect was not mediated by hs-CRP, suggesting that it is probably the hypercoagulability associated with VTE that drives atherosclerosis, which could also explain the increased risk of arterial thrombotic events following incident VTE. 89 Novel preclinical data were reported by Owens and colleagues showing that PAR-2 is a relevant mediator of proatherogenic effects;
PAR-2 deficient mice had smaller aortic plaques, possibly due to combined effects on cholesterol efflux from macrophages and attenuation of VSMC activity. 90 91 Posthuma and colleagues showed that rivaroxaban not only inhibited atherogenesis but even diminished existing lesions, the mechanisms of which need further study. 92 Data on hemostasis biomarkers of cardiovascular disease were reported by Komarov et al., showing that addition of D-dimer to wellknown scoring systems in patients after elective PCI could improve the diagnostic capacity to predict MACE in these patients. 93 Soluble thrombomodulin (sTM) was studied as a biomarker of endothelial injury in CAD patients by Komanasin and colleagues, reporting that raised plasma sTM was associated with increasing coronary artery stenosis. 94 Finally, Eggebrecht and colleagues studied the effects of 
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